Nurix Therapeutics, Inc. (NRIX) Stock Price & Analysis
Nurix Therapeutics, Inc. (NRIX) is trading at USD 15.86, down 1.77% today, as of November 10, 2026 at 16:53 UTC (US market open; quotes may be delayed), according to Nexqual market data.
NRIX last closed at USD 16.14; today's session has ranged USD 15.75–16.76 on volume of 1,039,059 shares. Market capitalization is $1.73B, with a 52-week range of USD 12.01–28.23 (NGM). Source: Nexqual, retrieved November 10, 2026 at 16:53 UTC.
What changed for NRIX since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 10, 2026).
- Nurix Therapeutics, Inc. (NRIX) stock went from USD 9.34 (close of the week of Aug 25, 2025, split-adjusted) to USD 15.85, a +69.8% price change; the S&P 500 (SPY) moved +17.4% over the same period.
- NRIX revenue over the last four reported quarters (through Aug 31, 2026) was $702M, +1186.8% vs $54.5M in fiscal year 2024 (ended Nov 30, 2024), the last full year filed before September 2025; net income -$194M → $295M (SEC 10-K / 10-Q).
- Analyst actions on NRIX in the last 120 days: 11 (6 upgrades or target raises, 3 downgrades or target cuts); most recent Wells Fargo, Nov 4, 2026.
Also available as compact Markdown for AI agents: nexqual.com/NRIX.md
Key facts (NRIX)
- Last four reported quarters (through Aug 31, 2026): revenue $702M, net income $295M (42.0% margin), free cash flow $370M (SEC filings).
- Valuation: P/E 5.9x.
- Analysts: Buy (mean 1.71 on a 1–5 scale) (14 analysts), mean target USD 33.5 (range 20–41).
- Total return with dividends: 1Y +29.4% vs S&P 500 +10.8%; 5Y -53.5% vs S&P 500 +70.9%.
- Next earnings: 2027-01-28 (date not yet confirmed by the company), EPS estimate USD 1.51, revenue estimate $288M.
- Dividend: NRIX paid no cash dividend in the last five years.
- Short interest: 19.06% of float (as of 2026-10-15), 10.3 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (NRIX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $29.8M | $38.6M | $77.0M | $54.5M | $84.0M | $702M |
| Operating income | -$118M | -$184M | -$155M | -$213M | -$286M | $290M |
| Net income | -$117M | -$180M | -$144M | -$194M | -$264M | $295M |
| EPS (diluted) | -$2.73 | -$3.71 | -$2.65 | -$2.88 | -$3.05 | — |
| Free cash flow | -$90.0M | -$172M | -$89.8M | -$182M | -$263M | $370M |
| Operating margin | -396.3% | -476.0% | -201.4% | -390.5% | -340.2% | 41.3% |
| Net margin | -393.9% | -466.9% | -187.0% | -354.9% | -314.9% | 42.0% |
| Revenue growth | +66.9% | +29.8% | +99.3% | -29.1% | +54.0% | — |
| Cash + short-term investments | $296M | $309M | $288M | $610M | $593M | — |
Fiscal years end Nov. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Aug 31, 2026) (NRIX)
P/E 5.9x · P/S 2.5x · P/FCF 4.7x · P/B 1.8x · FCF yield 21.35% · Earnings yield 17.02%
Analysts (NRIX)
Consensus Buy (mean 1.71 on a 1–5 scale), 14 analysts; mean target USD 33.5 (low 20, high 41).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-11-04 | Wells Fargo | Target lowered | Equal-Weight | $25 → $20 |
| 2026-10-16 | HC Wainwright & Co. | Target raised | Buy | $34 → $36 |
| 2026-10-13 | RBC Capital | Target lowered | Outperform | $36 → $35 |
| 2026-10-13 | Oppenheimer | Target raised | Outperform | $28 → $32 |
| 2026-10-13 | Truist Securities | Target lowered | Buy | $34 → $33 |
| 2026-10-13 | Baird | Target raised | Outperform | $33 → $36 |
| 2026-10-13 | Needham | Reiterated | Buy | $34 |
| 2026-08-10 | RBC Capital | Target raised | Outperform | $33 → $36 |
| 2026-08-04 | Needham | Reiterated | Buy | $34 |
| 2026-07-28 | Morgan Stanley | Target raised | Overweight | $36 → $38 |
| 2026-07-22 | UBS | Target raised | Buy | $23 → $31 |
Total return (dividends reinvested) (NRIX)
| 1Y (from 2025-11-10) | 5Y (from 2021-11-08) | |
|---|---|---|
| Total return | +29.4% | -53.5% |
| S&P 500 (SPY) | +10.8% | +70.9% |
| Per year | +29.4% | -14.2% |
| Volatility (annualized) | 72.8% | 74.5% |
| Max drawdown | -46.6% (Aug 2026→Nov 2026) | -87.1% (Nov 2021→Oct 2023) |
Dividends (NRIX)
NRIX paid no cash dividend in the last five years.
Short interest (NRIX)
20,607,897 shares sold short, 19.06% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 17,976,804 shares (+14.6%). Days to cover: 10.3 (short shares ÷ average daily volume).
NRIX earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Aug 31, 2026 | $4.73 | $5.02 | Miss −5.8% | — |
| — | Quarter ended May 31, 2026 | −$0.81 | −$0.72 | Miss −12.5% | — |
| — | Quarter ended Feb 28, 2026 | −$0.79 | −$0.76 | Miss −3.9% | — |
| — | Quarter ended Nov 30, 2025 | −$0.82 | −$0.92 | Beat +10.9% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
NRIX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Nov 2026) | $1.51 | $-0.37 | +$1.88 | $287.9M | 3 |
| Next quarter (ends Feb 2027) | $-0.59 | $-0.44 | −$0.15 | $15.0M | 1 |
| Current fiscal year (ends Nov 2026) | $3.02 | $1.79 | +69.0% | $744.8M | 3 |
| Next fiscal year (ends Nov 2027) | $-1.28 | $-1.44 | +$0.16 | $123.2M | 3 |
NRIX options: expected move
Options price a move of about ±40.4% (±$6.53) by Apr 16, 2027, which includes earnings on Jan 28, 2027; the earnings reaction alone is priced at about ±9.9%.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 10 | 121.3% | ±16.1% |
| Dec 18, 2026 | 38 | 120.3% | ±31.0% |
| Jan 15, 2027 | 66 | 76.9% | ±26.0% |
| Apr 16, 2027 | 157 | 78.5% | ±40.4% |
30-day implied volatility 84.6% vs 148.1% realized over the last 30 trading days. Put/call ratio (volume) 1.31. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of November 10, 2026 at 16:53 UTC)
| Price | USD 15.86 |
|---|---|
| Change | ▼ 1.77% (down) |
| Previous Close | USD 16.14 |
| Open | USD 16 |
| Day Range | USD 15.75 – 16.76 |
| 52-Week Range | USD 12.01 – 28.23 |
| Volume | 1,039,059 shares |
| Market Cap | $1.73B |
| Exchange | NGM |
Technical Analysis (NRIX)
Nexqual's technical model rates NRIX "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of November 10, 2026 at 16:53 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.88 (oversold) |
| vs SMA50 | Below (USD 23.86) |
| MACD | -2.09 (negative) |
Analyst Ratings (NRIX)
Wall Street analysts rate NRIX "Buy" based on 14 analysts, with a mean price target of USD 33.5 (range USD 20–41), per Nexqual as of November 10, 2026 at 16:53 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 33.5 |
| High Target | USD 41 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 13 / 1 / 0 |
Earnings (NRIX)
| Next Earnings Date | 2027-01-28 |
|---|---|
| EPS Estimate | USD 1.51 |
| Revenue Estimate | $287.86M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-08-31 | USD 4.73 vs est 5.02 ▼ miss |
| 2026-05-31 | USD -0.81 vs est -0.72 ▼ miss |
| 2026-02-28 | USD -0.79 vs est -0.76 ▼ miss |
| 2025-11-30 | USD -0.82 vs est -0.92 ▲ beat |
Source: Nexqual, November 10, 2026 at 16:53 UTC.
Financials & Fundamentals (NRIX)
| Total Revenue | $701.94M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +8426.30% |
| Gross Margin | +52.41% |
| Operating Margin | +83.12% |
| Profit Margin | +42.01% |
| ROE | +43.99% |
| Debt / Equity | 0.07 |
| Current Ratio | 8.44 |
| Total Cash | $1.05B |
| Total Debt | $65.33M |
| Free Cash Flow (last four quarters to Aug 2026, SEC 10-Q / 10-K) | $369.81M (52.7% of revenue) |
Source: Nexqual, November 10, 2026 at 16:53 UTC.
Financial Health Score (NRIX)
Nexqual rates Nurix Therapeutics, Inc.'s overall financial health "Strong" across five dimensions, as of November 10, 2026 at 16:53 UTC.
| Growth | Strong — Revenue +739% (last 4 quarters to Aug 2026 vs the 4 before, SEC) |
|---|---|
| Profitability | Strong — Gross margin 52%, operating 41% (last 12 months; the Aug 2026 quarter alone accounts for 193% of operating income) |
| Balance Sheet | Strong — $1.05B cash vs $65M debt, net cash position |
| Cash Flow | Strong — FCF $370M (last 4 quarters to Aug 2026, SEC), 53% margin |
| Efficiency | Strong — ROE 30%, ROA 24.7% (last 4 quarters, SEC) |
Ownership (NRIX)
| Insider Ownership | +1.03% |
|---|---|
| Institutional Ownership | +108.73% |
| Shares Outstanding | 109.25M |
| Float | 79.58M |
| Short % of Float | +19.06% |
Source: Nexqual, November 10, 2026 at 16:53 UTC.
Leadership (NRIX)
Nurix Therapeutics, Inc. is led by Arthur T. Sands, CEO, President & Director, per Nexqual as of November 10, 2026 at 16:53 UTC.
| CEO, President & Director | Arthur T. Sands |
|---|---|
| Chief Financial Officer | Johannes Van Houte |
| Chief Scientific Officer | Gwenn M. Hansen |
Major Backers & Investors (NRIX)
Notable institutional backers of Nurix Therapeutics, Inc. include Vestal Point Capital, LP, Deep Track Capital, Lp, Rubric Capital Management LP, according to Nexqual as of November 10, 2026 at 16:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Vestal Point Capital, LP | 7.37% |
| Deep Track Capital, Lp | 7.08% |
| Rubric Capital Management LP | 6.62% |
| FMR, LLC | 5.02% |
| Price (T.Rowe) Associates Inc | 4.98% |
| Morgan Stanley | 4.36% |
| Baker Bros. Advisors, LP | 4.26% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.03% |
| State Street | 4.28% |
| Vanguard Group | 4.11% |
Source: Nexqual, November 10, 2026 at 16:53 UTC.
From Nurix Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-01-28)
Key Strengths & Strategy (as disclosed to the SEC)
- We expect to earn multiple additional preclinical and clinical milestones across our three active partnerships in 2026, which may allow us to secure additional license and development candidate events in 2026 and subsequent years. •Advance our proprietary portfolio of preclinical programs toward additional INDs.
- By combining Nurix's experience in machine learning, automated chemistry and targeted protein degraders with Pfizer's expertise in antibody conjugate design, optimization and development, we believe we can achieve technical synergies that could allow us to redefine the application of antibody conjugates for not only oncology but also non-oncology indications. •Grow our proprietary pipeline by expanding the capabilities of our DEL-AI platform.
- Based on reported sales to date, global sales of this drug class, including Revlimid and Pomalyst, peaked in 2021 at approximately $16.2 billion, prior to the introduction of generic competition.
- Our approach uses comprehensive parallel screening campaigns to interrogate numerous states and surfaces of the target protein by combining multiple protein constructs with a variety of known substrates, binders, or cofactors in empirically replicated screening assays. •Proprietary data analysis and hit confirmation technologies.
Partnerships
- In our partnership with Pfizer, which was announced in September 2023 under an agreement with Seagen, Inc., we have achieved three preclinical milestones to date, qualifying for $15.0 million in milestone payments.
- As part of our strategy to accelerate DAC discovery and demonstrate value, we have partnered with Pfizer, the leading pharmaceutical company in the antibody drug conjugate space, to advance this cutting-edge modality.
Legal & Regulatory Risks (Item 1A, quoted)
- We have received Fast Track designation for bexobrutideg (NX-5948) and may seek Fast Track designation for other drug candidates in the future. Fast Track designation may not lead to faster development or regulatory review or approval process, and it does not increase the likelihood that our drug candidates will receive marketing approval.
- We may submit an NDA for our drug candidates under the Accelerated Approval pathway.
- We may submit an NDA for one or more of our drug candidates seeking approval through the Accelerated Approval Pathway.
- Failure to obtain marketing approval in foreign jurisdictions would prevent our drug candidates from being marketed abroad and may limit our ability to generate revenue from product sales.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | USD 137.08 | ▼ 1.28% |
| KOD | Kodiak Sciences Inc | USD 105.08 | ▼ 1.89% |
| ORKA | Oruka Therapeutics, Inc. | USD 104.82 | ▲ 0.25% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | USD 48.39 | ▼ 1.73% |
| AXSM | Axsome Therapeutics, Inc. | USD 138.75 | ▲ 3.57% |
| IMVT | Immunovant, Inc. | USD 35.45 | ▲ 0.85% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 10, 2026 at 16:53 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt